Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -18.50% | 40.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.50% | 40.33% | |||
| Cost of Revenue | -31.07% | 37.03% | |||
| Gross Profit | 75.63% | -26.48% | |||
| SG&A Expenses | -9.41% | 16.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.43% | 33.18% | |||
| Operating Income | 43.91% | -21.72% | |||
| Income Before Tax | 42.02% | -15.10% | |||
| Income Tax Expenses | -11.76% | -- | |||
| Earnings from Continuing Operations | 42.06% | -15.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.06% | -15.01% | |||
| EBIT | 43.91% | -21.72% | |||
| EBITDA | 45.91% | -24.07% | |||
| EPS Basic | 59.54% | 5.37% | |||
| Normalized Basic EPS | 59.51% | 3.49% | |||
| EPS Diluted | 59.54% | 5.37% | |||
| Normalized Diluted EPS | 59.51% | 3.49% | |||
| Average Basic Shares Outstanding | 43.18% | 21.54% | |||
| Average Diluted Shares Outstanding | 43.18% | 21.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||